Work

Durvalumab in ≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: Results from the phase 2 ATLANTIC study

Year: 2017

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx091.002

Authors: M.C. Garassino, B.-C. Cho, J.E. Gray, J. Mazières, K. Park, R.A. Soo, P. Dennis, Y. Huang, C. Wadsworth, N. Rizvi

Institutions: Fondazione IRCCS Istituto Nazionale dei Tumori, Yonsei University, Yonsei Cancer Hospital, Moffitt Cancer Center, Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, Samsung Medical Center, National University Hospital, AstraZeneca (United States), AstraZeneca (United Kingdom), Columbia University Irving Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Eli Lilly and Company, Pfizer, Celgene, F. Hoffmann-La Roche, Novocure, Yuhan, Kyowa Hakko Kirin, Astellas Pharma, Genentech

OpenAlex ID: W2612760980

FWCI: 3.26

Cites:

Cited by: 16

Related to: 10